Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for Caribou Biosciences (CRBU) over the last 5 years, with Q3 2025 value amounting to -$0.3.

  • Caribou Biosciences' EPS (Weighted Average and Diluted) rose 2105.26% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7, marking a year-over-year decrease of 240.96%. This contributed to the annual value of -$1.65 for FY2024, which is 1962.97% down from last year.
  • As of Q3 2025, Caribou Biosciences' EPS (Weighted Average and Diluted) stood at -$0.3, which was up 2105.26% from -$0.58 recorded in Q2 2025.
  • Over the past 5 years, Caribou Biosciences' EPS (Weighted Average and Diluted) peaked at $0.09 during Q4 2021, and registered a low of -$1.39 during Q2 2021.
  • For the 5-year period, Caribou Biosciences' EPS (Weighted Average and Diluted) averaged around -$0.44, with its median value being -$0.44 (2022).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 60000.0% in 2022, then soared by 7272.73% in 2023.
  • Caribou Biosciences' EPS (Weighted Average and Diluted) (Quarter) stood at $0.09 in 2021, then crashed by 600.0% to -$0.45 in 2022, then rose by 11.11% to -$0.4 in 2023, then dropped by 7.61% to -$0.43 in 2024, then surged by 30.3% to -$0.3 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.3 in Q3 2025, compared to -$0.58 in Q2 2025 and -$0.43 in Q1 2025.